Imagine a smart switch for your immune system that turns down the dangerous inflammation causing a cytokine storm without turning off your body's ability to fight the virus. It works like a shield that blocks the virus from replicating while keeping your natural defenses active. Because it's a pill, it's easy to take at home before a patient gets severely ill.
Current COVID-19 antivirals often have side effects or risk drug resistance due to mutations. There is a lack of safe, oral, early-intervention treatments that work across all viral variants without suppressing the patient's immune system.
A first-in-class drug candidate (MP1032) validated through a Phase IIa trial, along with a GMP-compliant API production process and an automated capsule-filling prototype.
If you are a drug developer dealing with the risk of viral mutations making current antivirals obsolete — this project developed MP1032 that is variant agnostic and effective against different SARS-CoV-2 strains.
If you are a hospital network dealing with high admission rates for moderate COVID-19 cases — this project developed an oral treatment that aims to halt disease progression in early stages to reduce hospitalization time.
If you are a GMP manufacturer dealing with the need for rapid scale-up of antiviral APIs — this project developed a GMP-compliant production process and a prototype for automated capsule filling.
Based on available project data, specific pricing or cost per dose is not mentioned, although the project highlights that production scale-up is intended to be affordable.
Yes, the project successfully developed a GMP-compliant production scale-up process for the active pharmaceutical ingredient (API) and a prototype for automated capsule filling.
Based on available project data, specific patent numbers or licensing terms are not provided, but the drug is described as a first-in-class candidate developed by a consortium of industry partners.
The project completed a Phase IIa clinical trial and ensured the clinical development plan aligns with regulatory requirements to prepare for Phase IIb/III trials.
The project aimed to have MP1032 ready to progress to Phase IIb/III trials by October 2022.
The consortium is highly industry-focused, consisting of 6 partners with a 100% industry ratio, including 3 SMEs. This structure suggests a strong commercial drive, as the group lacks academic partners and focuses entirely on clinical validation, GMP scale-up, and regulatory preparation.
Contact METRIOPHARM AG in Switzerland for licensing and Phase IIb/III partnership opportunities.
Contact SciTransfer to identify partners for Phase III clinical trials of MP1032.
